

GreenMark Biomedical Raises Seed Investment

Ann Arbor, MI – June 29, 2018 – GreenMark Biomedical Inc. today announced that it closed on \$500K in equity investment. The round is led by BlueWater Angel Investment Network (BWA) of Saginaw, MI and funds flowed in May and June as part of a Rolling Close. Biosciences Research & Commercialization Center (BRCC), an early stage Life Science Investor out of Kalamazoo, MI also participated. In addition, the round involved two early stage investors and convertible note holders, Mr. Scott Pundsack, J.D. and Dr. Glenn Jones, MD. The term sheet for this priced Series Seed Preferred round allows additional investors to come in up to \$1.0 million.

GreenMark is a minimally invasive healthcare company founded in 2016. The company is developing technologies that involve small biopolymer particles produced from natural corn starch. The company's diagnostic product is to be used by dental professionals as part of the routine dental exam, to better detect, assess and monitor non-invasive treatment of Dental Caries (tooth decay). The product, a mouth rinse containing fluorescent particles made from food grade starch, targets active cavities and illuminates them using a standard curing light found in every dental practice. At early stages before cavitation, non-surgical management options can be used, thus avoiding the dental drill, resulting in improved long term oral health outcomes for patients. The company is also developing a targeted treatment, to not only find the disease early but to improve non-invasive treatment aimed at preventing fully developed cavities.

"This investment allows GreenMark to further develop and commercialize its next generation diagnostic and therapeutic products for Dental Caries, the world's most prevalent chronic disease", explained Ken Kousky, President and Chairman for BWA. *"Given starch is degraded by natural enzymes in human saliva, starch nanoparticles are an ideal carrier for dental applications,"* added Stephen Haakenson, Executive Director for BRCC.

The technology platform enables loading of either water, drugs, minerals or other agents on the inside and placing targeting functionalities on the outside of the starch particles providing a general device for targeted biodelivery of health solutions. *"GreenMark has a unique bioresorbable delivery device and a strong platform for developing both dental and medical technologies,"* said Mr. Scott Pundsack, IP attorney for the company. *"Longer term I see great potential for this technology in the treatment of patients undergoing radiotherapy for head and neck cancers, who exhibit a higher incidence of Dental Caries, as well as in targeted anti-cancer drug delivery applications",* added Dr. Glenn Jones, MD, a practicing Radiation Oncologist and Clinical Investigator in St. John's, Antigua and Research Consultant, School of Clinical Research and Medicine, The University West Indies in Nassau, The Bahamas.

The company has received support from state and federal funding programs. *"We were awarded a Phase I SBIR grant by the National Institutes of Health, a strong endorsement for our dental technology, and combined with this Seed investment it allows us to drive our business development forward,"* said Dr. Steven Bloembergen, Ph.D., the company's Founder, Chairman and CEO. He added: *"I'm thrilled we were able to secure two Angel groups, including our lead investor, right here in our own backyard where we have also benefited from a Small Company Innovation Program (SCIP) grant and a Business Accelerator Fund (BAF) grant from the State of Michigan." "We're very grateful for the timely support from the state, as well as the multiple Michigan based mentors who rallied around us, helped sharpen our plan and made warm introductions for us with investors".*

About GreenMark Biomedical Inc.

GreenMark's central concept is biodelivery of health solutions on target, precisely where needed. The company has patented, patent-pending and proprietary technologies that use different grades of biobased nanoparticles uniquely modified into novel products that have built-in targeting performance for diagnostic & therapeutic dental and medical applications.

GreenMark Biomedical Inc. has an office located at 325 E. Grand River Avenue, Suite 314, East Lansing, MI 48823 and lab facilities at 1600 Huron Parkway, Building 520, 2nd Floor, Ann Arbor, MI 48109. Contact: info@greenmark.bio or (517) 896-3665.

<http://greenmark.bio/>

About BlueWater Angel Investment Network

BlueWater Angels (BWA) is a network of more than 50 high net-worth individuals and select organization interested in investing capital in promising companies with the expectation of receiving a substantial return on their investment. BWA's Mission: "Our goals are to bring together a large network of individuals to boost economic development and job creation, while increasing net-worth." Its Vision: "We believe the best way to predict the future is to invest in it." BWA has invested over \$18 million to date.

<http://bluewaterangels.com>

About Biosciences Research & Commercialization Center

Biosciences Research & Commercialization Center (BRCC) is based at Western Michigan University and was established in 2003 with a special \$10 million appropriation from the Michigan Legislature as a nonprofit investor, designed to provide seed funding to early-stage companies focused on the Life Science sector. BRCC considers a wide range of life science technologies across all indications, including but not limited to: biotech therapeutics, diagnostics, medical devices, software, agriculture, environmental and analytical services. BRCC also provides growth capital funding to Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) already servicing and on the market. The economic development focus of the BRCC aims to promote the growth of Michigan's life sciences business sector and collaborates with the state's entrepreneurial resource service providers.

<http://www.brcc.wmich.edu/>

###